# Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol

> **NCT05657704** · PHASE4 · UNKNOWN · sponsor: **Fundación de Investigación Biomédica - Hospital Universitario de La Princesa** · enrollment: 300 (estimated)

## Conditions studied

- Post-surgical Pain
- Pain, Acute
- Postoperative Pain

## Interventions

- **DRUG:** The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype

## Key facts

- **NCT ID:** NCT05657704
- **Lead sponsor:** Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-05
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657704, "Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05657704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*